Furthermore, dysregulated renalase signalling provides a survival advantage to cancer cells, and inhibition of renalase signalling using inhibitory antibodies not only has direct cytotoxic effect on tumour cells, but also modulates the immune response to tumour by shifting TAMs from a M2‐like tumour promoting phenotype to a M1‐like tumour inhibitory one. This evidence concerns the gene RNLS and cancer.